Viewing Study NCT00126893

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:14 AM
Ignite Modification Date: 2026-01-07 @ 10:21 AM
Study NCT ID: NCT00126893
Status: TERMINATED
Last Update Posted: 2007-05-15
First Post: 2005-08-03
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
Sponsor: Celgene Corporation
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Leukemia View
None AML View
None CC401 View
None CC-401 View
None Celgene View
None High Risk Myeloid Leukemia View
None Myeloid Leukemia View